source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Algenuity appoints new CSO

Algenuity, a leader in algal biology and industrial biotechnology, has appointed Dr Alex Pudney as the company’s chief scientific officer. Pudney brings extensive experience to the role, having previously worked in both research and start-ups addressing issues of sustainability and…

PhoreMost completes £11 million Series-A funding round

PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has completed an £11 million ($15 million) Series-A investment round which will be used to expand operations on the company’s premises on the Babraham Research Campus and progress several…

SYGNIS completes acquisition of TGR Biosciences

SYGNIS AG has completed the acquisition of Australian research reagents company TGR Biosciences, stating that TGR and its highly complementary technologies and products along with its strong customer base would significantly contribute to the overall performance of the SYGNIS Group.…

Glythera appoints Professor Kerry Chester to SAB

Antibody drug conjugate (ADC) development company Glythera Limited has appointed Professor Kerry Chester to its Scientific Advisory Board (SAB) to add to the SAB’s support in shaping its portfolio of ADCs for targeting previously untreatable cancers. Professor Chester leads the…

PATH and Mologic advance new malaria diagnostic test

International not-for-profit health innovator PATH and diagnostic test developer Mologic have entered an agreement to advance a new rapid diagnostic test to support the treatment and elimination of relapsing malaria (Plasmodium vivax). More than 2.5 billion people worldwide, mainly in…

PhoreMost and Plexxikon collaborate to identify novel drug targets

PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has signed a collaborative agreement with Daiichi Sankyo’s US-based small molecule structure-guided R&D centre Plexxikon Inc in which the company will apply its next-generation phenotypic screening platform, SITESEEKER®, towards…
Subscribe to this RSS feed